Drug lookup | Fillwise

CHLORPROMAZINE

3 general benefit · 3 not a benefit

Other products in the same Health Canada class (N05A) — coverage varies; not interchangeable

Aripiprazole (Abilify Asimtufii): general benefit
Asenapine (Saphris): general benefit
Brexpiprazole (Rexulti): general benefit
Cariprazine (Vraylar): general benefit
Flupentixol decanoate (Fluanxol Depot): general benefit
Flupentixol (Fluanxol): general benefit

18 more in the class list below

Teva-Chlorpromazine · DIN 00232823 · 25mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Teva-Chlorpromazine · DIN 00232823 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2011-03-09 · brand TEVA-CHLORPROMAZINE · ATC N05AA01 CHLORPROMAZINE · form Tablet · route Oral · ingredients CHLORPROMAZINE (CHLORPROMAZINE HYDROCHLORIDE) 25.0 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Chlorpromazine: Formulary list price $0.2454/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2454 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1294 · Verify on the e-Formulary ↗ (DIN 00232823)

Source record

DIN 00232823: Teva-Chlorpromazine Raw flags: sec3=Y Item: 281608009; group id 484; item number 1234; lccId None; manufacturer id TEV Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.2454; ministry $0.2454 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00232823 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1294

Interchangeable products

Largactil · DIN 01929917 · not recorded

Shortage status: resolved shortage (ended 2025-11-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00232823

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Chlorpromazine · DIN 00232807 · 50mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Teva-Chlorpromazine · DIN 00232807 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2011-03-09 · brand TEVA-CHLORPROMAZINE · ATC N05AA01 CHLORPROMAZINE · form Tablet · route Oral · ingredients CHLORPROMAZINE (CHLORPROMAZINE HYDROCHLORIDE) 50.0 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Chlorpromazine: Formulary list price $0.2808/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2808 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 00232807: Teva-Chlorpromazine Raw flags: sec3=Y Item: 281608008; group id 484; item number 1235; lccId None; manufacturer id TEV Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.2808; ministry $0.2808 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00232807 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1293

Interchangeable products

Largactil · DIN 01929925 · not recorded

Shortage status: resolved shortage (ended 2025-06-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00232807

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Chlorpromazine · DIN 00232831 · 100mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Teva-Chlorpromazine · DIN 00232831 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2011-03-09 · brand TEVA-CHLORPROMAZINE · ATC N05AA01 CHLORPROMAZINE · form Tablet · route Oral · ingredients CHLORPROMAZINE (CHLORPROMAZINE HYDROCHLORIDE) 100 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Chlorpromazine: Formulary list price $0.7475/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7475 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 00232831: Teva-Chlorpromazine Raw flags: sec3=Y Item: 281608007; group id 484; item number 1236; lccId None; manufacturer id TEV Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.7475; ministry $0.7475 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00232831 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1295

Interchangeable products

Largactil · DIN 01929933 · not recorded

Shortage status: resolved shortage (ended 2025-11-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00232831

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Largactil · PIN 01929917 · 25mg · tablet

Listed, not a benefitOntario PIN; no Health Canada record under this code

StatusListed, not a benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Largactil · DIN 01929917 Manufacturer: Rhone-Poulenc Rorer-Ethical Division; listing date 1999-07-22 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check this DIN again

Largactil: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 01929917)

Source record

DIN 01929917: Largactil Raw flags: notABenefit=Y, sec3=Y Item: 281608009; group id 484; item number 1234; lccId None; manufacturer id RPP Source form: Tab; strength: 25mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01929917 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Interchangeable products

Teva-Chlorpromazine · DIN 00232823 · $0.2454

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01929917

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Largactil · PIN 01929925 · 50mg · tablet

Listed, not a benefitOntario PIN; no Health Canada record under this code

StatusListed, not a benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Check Health Canada brand search

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Largactil · DIN 01929925 Manufacturer: Rhone-Poulenc Rorer-Ethical Division; listing date 1999-07-22 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check this DIN again

Largactil: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 01929925)

Source record

DIN 01929925: Largactil Raw flags: notABenefit=Y, sec3=Y Item: 281608008; group id 484; item number 1235; lccId None; manufacturer id RPP Source form: Tab; strength: 50mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01929925 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Interchangeable products

Teva-Chlorpromazine · DIN 00232807 · $0.2808

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Largactil · PIN 01929933 · 100mg · tablet

Listed, not a benefitOntario PIN; no Health Canada record under this code

StatusListed, not a benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Check Health Canada brand search

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Largactil · DIN 01929933 Manufacturer: Rhone-Poulenc Rorer-Ethical Division; listing date 1999-07-22 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check this DIN again

Largactil: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 01929933)

Source record

DIN 01929933: Largactil Raw flags: notABenefit=Y, sec3=Y Item: 281608007; group id 484; item number 1236; lccId None; manufacturer id RPP Source form: Tab; strength: 100mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01929933 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Interchangeable products

Teva-Chlorpromazine · DIN 00232831 · $0.7475

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

FLUPENTIXOL DECANOATE

· 2 products · General benefit · strengths: 20mg/mL, 100mg/mL · Inj Sol-1mL Amp Pk

FLUPENTIXOL DIHYDROCHLORIDE

· 2 products · General benefit · strengths: 0.5mg, 3mg · Tab

FLUPHENAZINE HCL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 1mg, 2mg, 5mg · Tab

HALOPERIDOL

· 14 products · Listed, not a benefit (7), General benefit (7) · strengths: 5mg/mL, 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg · Inj Sol-1mL Pk, Tab

LOXAPINE SUCCINATE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 5mg, 10mg, 25mg, 50mg · Tab

LURASIDONE HYDROCHLORIDE

· 38 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4), General benefit (33), Listed, not a benefit (1) · strengths: 20mg, 40mg, 60mg, 80mg, 120mg · Tab

OLANZAPINE

· 116 products · General benefit (99), Off-Formulary Interchangeable, not an ODB benefit (17) · strengths: 5mg, 10mg, 15mg, 20mg, 2.5mg, 7.5mg · Rapid Dissolve Tab, Tab

PALIPERIDONE

· 3 products · General benefit · strengths: 3mg, 6mg, 9mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more

Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

INDICATIONS AND CLINICAL USE TEVA-CHLORPROMAZINE (Chlorpromazine Hydrochloride) is indicated for:  Management of psychotic disorders such as schizophrenia.  Prevention and treatment of nausea and vomiting when other agents are ineffective or unavailable. Geriatrics (> 65 years of age): TEVA-CHLORPROMAZINE is not indicated in elderly patients with dementia. The safety and efficacy of TEVA-CHLORPROMAZINE in patients 65 years of age or older have not been studied (see WARNINGS AND PRECAUTIONS, Serious Warnings and Precautions Box and Special Populations). Pediatrics (< 18 years of age): The safety and efficacy of TEVA-CHLORPROMAZINE in children under the age of 18 have not been studied (see WARNINGS AND PRECAUTIONS, Special Populations). https://pdf.hres.ca/dpd_pm/00018580.PDF PM date: not printed or not captured Source product: TEVA-CHLORPROMAZINE; DIN 00232807; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Largactil: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026